Atea Pharmaceuticals (AVIR) CFO reports RSU vesting and 180,000-share stock option grant

Rhea-AI Filing Summary

Atea Pharmaceuticals officer Andrea Corcoran reported equity compensation activity. On January 31, 2026, previously granted restricted stock units converted into 54,866 shares of Atea common stock at no cash cost. To cover taxes, 16,104 of these shares were withheld at a price of $4.24 per share.

After these transactions, Corcoran directly owned 763,576 Atea common shares. She also received a new stock option covering 180,000 shares at an exercise price of $4.24 per share. This option vests in 48 equal monthly installments after January 31, 2026 and is fully vested by January 31, 2030.

Insider Trade Summary

54,866 shares exercised/converted

Mixed 5 txns

Insider Corcoran Andrea

Role See Remarks

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	44,366	$0.00	--
Exercise	Restricted Stock Units	10,500	$0.00	--
Grant/Award	Stock Option (Right to Buy)	180,000	$0.00	--
Exercise	Common Stock	54,866	$0.00	--
Tax Withholding	Common Stock	16,104	$4.24	$68K

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Stock Option (Right to Buy) — 180,000 shares (Direct); Common Stock — 779,680 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Includes 7,507 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan. The original grant of 133,100 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corcoran Andrea

(Last) (First) (Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		M		54,866	A	(1)	779,680(2)	D
Common Stock	01/31/2026		F		16,104	D	$4.24	763,576	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/31/2026		M			44,366	(3)	(3)	Common Stock	44,366	$0	0	D
Restricted Stock Units	(1)	01/31/2026		M			10,500	(4)	(4)	Common Stock	10,500	$0	0	D
Stock Option (Right to Buy)	$4.24	01/31/2026		A		180,000		(5)	01/30/2036	Common Stock	180,000	$0	180,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. Includes 7,507 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.

3. The original grant of 133,100 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.

4. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.

5. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

Remarks:

Chief Financial Officer, Executive Vice President, Legal and Secretary

	/s/ Andrea Corcoran	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Atea Pharmaceuticals (AVIR) report for Andrea Corcoran?

Andrea Corcoran reported RSU vesting, tax share withholding, and a new option grant. RSUs converted into 54,866 common shares, 16,104 shares were withheld at $4.24 for taxes, and she received a stock option for 180,000 shares vesting monthly through January 31, 2030.

How many Atea Pharmaceuticals (AVIR) shares does Andrea Corcoran own after this Form 4?

Andrea Corcoran directly owns 763,576 Atea common shares after these transactions. This reflects RSUs converting into shares and 16,104 shares withheld to satisfy tax obligations, as disclosed, leaving a reported post-transaction direct ownership balance of 763,576 shares.

What are the terms of Andrea Corcoran’s new Atea Pharmaceuticals (AVIR) stock option?

The new stock option covers 180,000 Atea common shares at a $4.24 exercise price. It vests in forty-eight equal monthly installments following January 31, 2026, becoming fully vested on January 31, 2030, giving long-term equity-based compensation tied to company performance.

What happened to Andrea Corcoran’s restricted stock units at Atea Pharmaceuticals (AVIR)?

Previously granted RSUs fully vested and converted into common shares on January 31, 2026. 44,366 and 10,500 RSUs were converted, totaling 54,866 shares. Each RSU represents a right to receive one Atea common share, according to the filing footnotes.

Why were 16,104 Atea Pharmaceuticals (AVIR) shares reported with transaction code F?

Code F indicates shares withheld to pay taxes on equity vesting. On January 31, 2026, 16,104 Atea common shares were withheld at $4.24 per share in connection with RSU vesting, reducing the net shares retained while satisfying tax obligations.

What executive role does Andrea Corcoran hold at Atea Pharmaceuticals (AVIR)?

Andrea Corcoran serves as Chief Financial Officer, Executive Vice President, Legal and Secretary. Her Form 4 reports equity compensation-related transactions, including RSU conversions, tax-related share withholding, and a substantial new stock option grant tied to continued service.